Keywords: Japan, AstraZeneca, Daiichi Sankyo, Denosumab, Xgeva, Sosei, NorLevo
In Japan, AstraZeneca to co-promote denosumab with Daiichi; Sosei debuts NorLevo
Article | 24 May 2011
Anglo-Swedish drug major AstraZeneca (LSE: AZN) today announced a co-promotion agreement in Japan with locally based Daiichi Sankyo (TSO: 4568) for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
